BDRX vs. ENTO, LIPO, HOTH, DRUG, EVOK, PCSA, VIRI, ARTL, CPHI, and KZIA
Should you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include Entero Therapeutics (ENTO), Lipella Pharmaceuticals (LIPO), Hoth Therapeutics (HOTH), Bright Minds Biosciences (DRUG), Evoke Pharma (EVOK), Processa Pharmaceuticals (PCSA), Virios Therapeutics (VIRI), Artelo Biosciences (ARTL), China Pharma (CPHI), and Kazia Therapeutics (KZIA). These companies are all part of the "pharmaceutical preparations" industry.
Biodexa Pharmaceuticals (NASDAQ:BDRX) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk.
Biodexa Pharmaceuticals has higher revenue and earnings than Entero Therapeutics.
Biodexa Pharmaceuticals received 1 more outperform votes than Entero Therapeutics when rated by MarketBeat users.
Biodexa Pharmaceuticals has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Entero Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.
Biodexa Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 715.49%. Given Biodexa Pharmaceuticals' higher probable upside, research analysts clearly believe Biodexa Pharmaceuticals is more favorable than Entero Therapeutics.
Biodexa Pharmaceuticals' return on equity of 0.00% beat Entero Therapeutics' return on equity.
In the previous week, Biodexa Pharmaceuticals had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for Biodexa Pharmaceuticals and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat Biodexa Pharmaceuticals' score of 0.63 indicating that Entero Therapeutics is being referred to more favorably in the news media.
17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Comparatively, 0.5% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Biodexa Pharmaceuticals beats Entero Therapeutics on 10 of the 12 factors compared between the two stocks.
Get Biodexa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodexa Pharmaceuticals Competitors List
Related Companies and Tools
